Portable: Compact and portable, allowing for immediate access and use anywhere

Heres why this move deserves attention Big Bet on a Blockbuster Segment Entry into the fast-growing GLP-1 (semaglutide) space Taps into a market set to explode with rising diabetes & obesity cases Timed perfectly post patent expiry early-mover advantage Product That Matches Global Standards Once-weekly injectable better patient adherence Available in 2 mg & 4 mg pre-filled pens Backed by Phase III data comparable efficacy + strong safety Premium Generic Strategy (Not a Price WarYet) Priced at ~4,200/month Positioned as a trusted, high-quality branded generic Targets urban, quality-conscious patients over deep discounting Full-Stack Manufacturing Power API + formulation + delivery device all in-house Strong edge in complex peptides & scale-up capability Sets the stage for global expansion Beyond Drug: Building a Patient Ecosystem SemaKare support program Focus on adherence, education & outcomes Shift from product-selling solution-building Competitive Storm Incoming Multiple Indian pharma giants entering semaglutide Likely outcomes: Price erosion Wider access Massive market expansion The Real Play

B12 deficiency is far more common than most people realise, and even a mild shortfall can cause significant and debilitating symptoms including persistent fatigue and low energy, brain fog and poor concentration, low mood and irritability, muscle weakness, and tingling or numbness in the hands and feet
The road to finding GLP-1 By the time Goodman had identified the gene for somatostatin another postdoctoral researcher called Pauline Kay Lund (figure 22) had also joined Haberners laboratory